Please login to the form below

Not currently logged in
Email:
Password:

AZ’s Gabriel Baertschi joins Grünenthal as CEO

He also becomes chairman of the corporate executive board

Grunenthal Gabriel BaertschiAachen, Germany-headquartered Grünenthal has named AstraZeneca's Gabriel Baertschi as its new chief executive officer, with effect from 1 October.

He succeeds Dr Eric-Paul Pâques who was appointed to the role in 2013, and retires at the end of the year.

Baertschi moves to the independent pharmaceutical firm from AstraZeneca, where he currently serves as country president for the company's operations in Japan.

Prior to taking up this role three years ago, Baertschi was AZ's country president for Germany and has led a number of its other operations in emerging markets.

Dr Wilhelm Moll, chairman of Grüenthal's supervisory board, said: “We are delighted that Gabriel Baertschi will join Grüenthal Group as chief executive officer.

“His deep experience in growing the business and developing the organisation in major developed and emerging markets will be a great asset for Grünenthal.

“He joins us at an exciting time when our strategy of expanding our strategic partnerships in research and development in Europe as well as in Latin America are accelerating our global growth.”

Dr Moll added: “We would like to thank Prof Dr Pâques for his outstanding leadership, integrity and extraordinary personal commitment for the future of a successful Grüenthal.”

15th June 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....